Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
All
Crypto
Stocks
Commodities & Forex
Macro
Fantastic Four Reasons Why Dogecoin’s 6% Bounce Could Extend Further
Fantastic Four Reasons Why Dogecoin’s 6% Bounce Could Extend Further

Dogecoin price climbed 6% to $0.231, with both on-chain signs and technical patterns hinting at further upside. Traders now eye $0.248 as the next key level.

BeInCrypto·2025/09/08 01:03
Hedera (HBAR) Price Awaits a Break to Escape Sideways Trap
Hedera (HBAR) Price Awaits a Break to Escape Sideways Trap

Hedera’s HBAR token remains range-bound with weakening volatility. Traders await a breakout from the $0.2109–$0.2237 trap for direction.

BeInCrypto·2025/09/08 01:00
Dogecoin ETF Hype and Retail Demand Spark Bullish Outlook for DOGE in September
Dogecoin ETF Hype and Retail Demand Spark Bullish Outlook for DOGE in September

Retail investors are flocking to Dogecoin in September as ETF approval odds surge and accumulation trends hint at a potential rally. Analysts predict prices could climb toward $1.4 by year’s end.

BeInCrypto·2025/09/08 00:08
Goldman and T. Rowe sign $1 billion partnership as Wall Street targets retirement cash
Goldman and T. Rowe sign $1 billion partnership as Wall Street targets retirement cash

Share link:In this post: Goldman Sachs is buying a $1 billion, 3.5% stake in T. Rowe Price to push private assets into retirement accounts. The partnership will launch target-date funds, co-branded portfolios, and advice services by mid-2025. Citigroup also announced a deal giving BlackRock $80 billion in client assets to manage starting in Q4.

Cryptopolitan·2025/09/07 23:50
Bitmain is hit with a lawsuit alleging breach of hosting agreement
Bitmain is hit with a lawsuit alleging breach of hosting agreement

Share link:In this post: Old Const says Bitmain faked breaches to end their deal and seize mining equipment. The company wants a court order stating that disputes must stay in Texas based on the agreement. Old Const is seeking an injunction, damages, and legal fees from Bitmain.

Cryptopolitan·2025/09/07 23:50
Fed chair contender Hassett slams central bank for mission creep and fading independence
Fed chair contender Hassett slams central bank for mission creep and fading independence

Share link:In this post: Kevin Hassett accused the Fed of losing independence and overstepping its mandate. He slammed the job data system as broken and called for urgent modernization. Kevin backed a full review of the Fed’s roles in policy, regulation, and research.

Cryptopolitan·2025/09/07 23:50
El Salvador joins the gold rush and acquires 13,999 troy ounces
El Salvador joins the gold rush and acquires 13,999 troy ounces

Share link:In this post: El Salvador’s central bank bought 13,999 troy ounces of gold worth $50 million. The bank says gold will diversify reserves and provide stability, especially as Bitcoin holdings remain volatile. The move follows the global trend of central banks buying over 1,000 tonnes of gold collectively.

Cryptopolitan·2025/09/07 23:50
Flash
11:06
Pasithea Therapeutics Corp. announced that its candidate drug Pas-4 demonstrated a favorable safety profile in clinical studies.
Data shows that all observed drug-related adverse events were either grade 1 or 2, with no higher-level (grade 3 or above) safety incidents reported. This positive safety data provides an important foundation for the subsequent clinical development of Pas-4. Typically, demonstrating controllable safety in early clinical trials is a key prerequisite for advancing to later-stage research. Investors and analysts generally prioritize the safety profile of biopharmaceutical company candidate drugs, as it directly impacts their prospects for regulatory approval and commercialization potential. The company stated that it will continue to advance Pas-4’s research programs and evaluate its therapeutic potential in the target indications.
11:04
Truist Securities has upgraded its investment rating for Fortune Brands Innovations Inc. from "Hold" to "Buy".
At the same time, the institution significantly raised its target stock price from $45 to $70.
11:04
Pasithea Therapeutics announced positive interim data from its Phase 1 study targeting advanced cancer.
Data shows that the therapy demonstrates good long-term safety and tolerability, and exhibits sustained clinical activity in patient groups previously treated with Mek/Braf inhibitors. Based on these positive results, the company has decided to expand the research program.
News